SCHEMBL6487394

SCHEMBL6487394

CC(C)(C)OC(=O)N(CCc1cc(N)ccn1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.46
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
OPRD1 P41143 1/20 0.35
KDM4E B2RXH2 3/20 0.35
SSTR4 P31391 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
GBA1 P04062 1/20 0.34
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678971 0.84 TP53 (0.39) ALDH1A1SMN1; SMN2MEN1CYP3A4CYP2C9
SCHEMBL6487391 0.83 KDM4E (0.41) F2ALDH1A1MEN1CYP3A4CYP2C9
SCHEMBL6489441 0.83 F2 (0.44) F2ALDH1A1SMN1; SMN2MEN1CYP3A4
SCHEMBL6492221 0.79 F2 (0.39) F2SMN1; SMN2MEN1CYP3A4CYP2C9
SCHEMBL6796112 0.78 MEN1 (0.41) F2MEN1KMT2ATDP1
SCHEMBL6645327 0.77 ALDH1A1 (0.43) F2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6648457 0.76 F2 (0.40) F2ALDH1A1MEN1CYP3A4KMT2A
SCHEMBL25920624 0.75 CHRM2 (0.44) F2ALDH1A1SMN1; SMN2MEN1CYP3A4
SCHEMBL9407535 0.75 MEN1 (0.50) F2ALDH1A1SMN1; SMN2MEN1CYP3A4
SCHEMBL6796397 0.73 SMO (0.41) F2ALDH1A1KDM4EHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 F2 1399/4885ALDH1A1 1427/4885SMN1; SMN2 2504/4885
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR F2 1415/4885ALDH1A1 2174/4885SMN1; SMN2 1836/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 F2 62/4885ALDH1A1 1603/4885SMN1; SMN2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.